Assessment of the Subcutaneous Reinjection of Human Autologous Adipose-derived Stromal Vascular Fraction (Celution® System) in the Hands of Patients Suffering From Systemic Sclerosis

Trial Profile

Assessment of the Subcutaneous Reinjection of Human Autologous Adipose-derived Stromal Vascular Fraction (Celution® System) in the Hands of Patients Suffering From Systemic Sclerosis

Completed
Phase of Trial: Phase II

Latest Information Update: 05 Dec 2016

At a glance

  • Drugs ECCS 50 (Primary)
  • Indications Systemic scleroderma
  • Focus Therapeutic Use
  • Acronyms SCLERADEC I
  • Most Recent Events

    • 05 Dec 2016 According to a Cytori Therapeutics media release, full data set of this trial will be presented by the Investigators at a forthcoming scientific meeting.
    • 05 Dec 2016 Topline review of early three-year follow-up data published in the Cytori Therapeutics Media Release
    • 29 Nov 2016 According to a Cytori Therapeutics media release, the two years follow-up results from this study were published in the journal of Current Research in Translational Medicine.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top